{"component": "definition", "props": {"groups": [{"samples": [{"hash": "72seS1H82Gs", "uri": "/contracts/72seS1H82Gs#terminated-program", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 30.8261470795, "published": true}, {"hash": "lRoAteVMpjC", "uri": "/contracts/lRoAteVMpjC#terminated-program", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 21.1724853516, "published": true}], "snippet": "means (a) with respect to the termination of this Agreement with respect to a Program pursuant to Sections 9.2(a), 9.2(b) or 9.2(d), the Program subject to such termination; and (b) with respect to termination of this Agreement in its entirety, both Programs.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [10, 25]}, {"key": "the-termination", "type": "clause", "offset": [26, 41]}, {"key": "pursuant-to-sections", "type": "clause", "offset": [86, 106]}, {"key": "the-program", "type": "clause", "offset": [133, 144]}, {"key": "subject-to", "type": "clause", "offset": [145, 155]}, {"key": "termination-of-this-agreement-in-its-entirety", "type": "clause", "offset": [198, 243]}], "size": 5, "hash": "f02b87b637e9a0bfcbfc4360ce673f3e", "id": 1}, {"samples": [{"hash": "7hMGGkEsXt0", "uri": "/contracts/7hMGGkEsXt0#terminated-program", "label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "score": 36.575633128, "published": true}, {"hash": "7AmF4p653oI", "uri": "/contracts/7AmF4p653oI#terminated-program", "label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "score": 27.4394245148, "published": true}, {"hash": "3jW9vRfQShD", "uri": "/contracts/3jW9vRfQShD#terminated-program", "label": "Strategic Collaboration Agreement (Isis Pharmaceuticals Inc)", "score": 26.8535251617, "published": true}], "snippet": "has the meaning set forth in Section 10.3.1.", "snippet_links": [], "size": 4, "hash": "7c30d795b9497c3da1849d410e9c11b0", "id": 2}, {"samples": [{"hash": "blku6Bo9ZuQ", "uri": "/contracts/blku6Bo9ZuQ#terminated-program", "label": "Collaboration and License Agreement (Voyager Therapeutics, Inc.)", "score": 30.1526355743, "published": true}, {"hash": "7nAWRZUMC7e", "uri": "/contracts/7nAWRZUMC7e#terminated-program", "label": "Collaboration and License Agreement (Neurocrine Biosciences Inc)", "score": 30.1033535004, "published": true}, {"hash": "bKqULuwAULe", "uri": "https://neurocrine.gcs-web.com/static-files/f6dfc4e3-1fc6-4220-8bf4-38abc35a7a82", "label": "neurocrine.gcs-web.com", "score": 9.613278389, "published": false}], "snippet": "means a Program that is terminated by the JSC pursuant to Section 3.1.2(q), by the mutual agreement of the Parties or pursuant to Article 14.", "snippet_links": [{"key": "pursuant-to-section", "type": "definition", "offset": [46, 65]}, {"key": "mutual-agreement-of-the-parties", "type": "clause", "offset": [83, 114]}, {"key": "article-14", "type": "definition", "offset": [130, 140]}], "size": 4, "hash": "a2c0a64b322913ed11c55b47003012ec", "id": 3}, {"samples": [{"hash": "lNYrtxpSCEZ", "uri": "/contracts/lNYrtxpSCEZ#terminated-program", "label": "Collaboration and License Agreement (Zai Lab LTD)", "score": 32.603012085, "published": true}, {"hash": "hZ4t2oTkw2D", "uri": "/contracts/hZ4t2oTkw2D#terminated-program", "label": "Collaboration and License Agreement (Macrogenics Inc)", "score": 32.57289505, "published": true}, {"hash": "lxfjxuf8CK6", "uri": "http://ir.macrogenics.com/static-files/26c45914-05f5-4c1d-a58c-62d342129a6a", "label": "ir.macrogenics.com", "score": 8.786447525, "published": false}], "snippet": "means any Program that is terminated by a Party pursuant to Section 16.2, Section 16.3, Section 16.4, Section 16.5, Section 16.6 or Section 16.7.", "snippet_links": [{"key": "by-a-party", "type": "clause", "offset": [37, 47]}, {"key": "section-162", "type": "clause", "offset": [60, 72]}, {"key": "section-163", "type": "clause", "offset": [74, 86]}, {"key": "section-164", "type": "clause", "offset": [88, 100]}, {"key": "section-165", "type": "clause", "offset": [102, 114]}, {"key": "section-166", "type": "clause", "offset": [116, 128]}, {"key": "section-167", "type": "clause", "offset": [132, 144]}], "size": 3, "hash": "ef38f19db7cca66512f26ec8f88943de", "id": 4}, {"samples": [{"hash": "eFoF27uKep1", "uri": "/contracts/eFoF27uKep1#terminated-program", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 28.4934978485, "published": true}, {"hash": "kQo3dtnEIk9", "uri": "/contracts/kQo3dtnEIk9#terminated-program", "label": "Collaboration and License Agreement (Merus N.V.)", "score": 28.3210124969, "published": true}, {"hash": "ihpnP4LePsf", "uri": "/contracts/ihpnP4LePsf#terminated-program", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 28.1211490631, "published": true}], "snippet": "means (a) with respect to the termination of this Agreement with respect to a Program pursuant to Sections 10.2(a), 10.2(b), or 10.2(c), the Program subject to such termination, including all of the associated Licensed Antibodies and Licensed Products, and (b) with respect to termination of this Agreement in its entirety, all Programs and all of the associated Licensed Antibodies and Licensed Products; provided that, if a Program becomes a Terminated Program prior to Program Selection and prior to expiration of the Research Term, it shall be treated under this Agreement as a Dropped Program.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [10, 25]}, {"key": "the-termination", "type": "clause", "offset": [26, 41]}, {"key": "pursuant-to-sections", "type": "clause", "offset": [86, 106]}, {"key": "the-program", "type": "clause", "offset": [137, 148]}, {"key": "subject-to", "type": "clause", "offset": [149, 159]}, {"key": "licensed-antibodies", "type": "definition", "offset": [210, 229]}, {"key": "licensed-products", "type": "clause", "offset": [234, 251]}, {"key": "termination-of-this-agreement-in-its-entirety", "type": "clause", "offset": [277, 322]}, {"key": "all-programs", "type": "definition", "offset": [324, 336]}, {"key": "provided-that", "type": "definition", "offset": [406, 419]}, {"key": "prior-to", "type": "definition", "offset": [463, 471]}, {"key": "program-selection", "type": "definition", "offset": [472, 489]}, {"key": "expiration-of-the-research-term", "type": "clause", "offset": [503, 534]}], "size": 3, "hash": "c3b3ccc58d0f9b342eccaad391112123", "id": 5}, {"samples": [{"hash": "6zY23TDFh7A", "uri": "/contracts/6zY23TDFh7A#terminated-program", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4483222961, "published": true}, {"hash": "cBiWK15Lw3n", "uri": "/contracts/cBiWK15Lw3n#terminated-program", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4072551727, "published": true}, {"hash": "b285ETTr4rL", "uri": "/contracts/b285ETTr4rL#terminated-program", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.3853530884, "published": true}], "snippet": "means: (a) any Research Program with respect to which \u2587\u2587\u2587\u2587\u2587\u2587\u2587 did not exercise an Option in accordance with Section 3.2 (Option Exercise) prior to the expiration of the Option Period for such Research Program, (b) any Research Program that is the subject of termination of this Agreement or for which \u2587\u2587\u2587\u2587\u2587\u2587\u2587 exercises its remedy in lieu of termination as set forth in Section 14.7 (Alternative Remedy in Lieu of Termination) or (c) any Research Program for which the Target that is the subject of such Research Program is replaced pursuant to a Replacement Decision.", "snippet_links": [{"key": "research-program", "type": "definition", "offset": [15, 31]}, {"key": "with-respect-to", "type": "clause", "offset": [32, 47]}, {"key": "in-accordance-with", "type": "clause", "offset": [89, 107]}, {"key": "section-32", "type": "clause", "offset": [108, 119]}, {"key": "option-exercise", "type": "clause", "offset": [121, 136]}, {"key": "prior-to-the", "type": "clause", "offset": [138, 150]}, {"key": "the-option-period", "type": "clause", "offset": [165, 182]}, {"key": "subject-of", "type": "clause", "offset": [247, 257]}, {"key": "agreement-or", "type": "definition", "offset": [278, 290]}, {"key": "section-147", "type": "clause", "offset": [369, 381]}, {"key": "alternative-remedy-in-lieu-of-termination", "type": "clause", "offset": [383, 424]}, {"key": "the-target", "type": "clause", "offset": [464, 474]}, {"key": "pursuant-to-a", "type": "clause", "offset": [532, 545]}], "size": 3, "hash": "c2ade010128d9da8a284081977e3e04d", "id": 6}, {"samples": [{"hash": "bDHpblDBppT", "uri": "/contracts/bDHpblDBppT#terminated-program", "label": "Collaboration Agreement", "score": 35.3063354492, "published": true}, {"hash": "9pPqYQEbiPt", "uri": "/contracts/9pPqYQEbiPt#terminated-program", "label": "Collaboration Agreement (Morphic Holding, Inc.)", "score": 30.4483222961, "published": true}, {"hash": "cZZE7vACrm6", "uri": "/contracts/cZZE7vACrm6#terminated-program", "label": "Collaboration Agreement (Morphic Holding, Inc.)", "score": 30.4072551727, "published": true}], "snippet": "has the meaning given in Section 2.j.", "snippet_links": [], "size": 3, "hash": "81d834caeb9c304f8db26cb44a0b8b12", "id": 7}, {"samples": [{"hash": "k6ioPFDpuhr", "uri": "/contracts/k6ioPFDpuhr#terminated-program", "label": "Collaboration, License and Option Agreement (Curis Inc)", "score": 32.2032852173, "published": true}, {"hash": "a2jP81icHKG", "uri": "/contracts/a2jP81icHKG#terminated-program", "label": "Collaboration, License and Option Agreement", "score": 31.3408622742, "published": true}, {"hash": "dO0MNV8xez7", "uri": "/contracts/dO0MNV8xez7#terminated-program", "label": "Collaboration, License and Option Agreement (Curis Inc)", "score": 26.1471595764, "published": true}], "snippet": "means:", "snippet_links": [], "size": 3, "hash": "0958f1425f29c6b4385536c9eb33667c", "id": 8}, {"samples": [{"hash": "kckpE6TS4II", "uri": "/contracts/kckpE6TS4II#terminated-program", "label": "Collaboration and License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 26.2402458191, "published": true}, {"hash": "1NM8pwgaDku", "uri": "/contracts/1NM8pwgaDku#terminated-program", "label": "Collaboration and License Agreement (Marika Inc.)", "score": 25.9609851837, "published": true}], "snippet": "shall have the meaning set forth in Section 12.5.", "snippet_links": [], "size": 3, "hash": "ce0f3de9f5dfde7cf77da8a78bc8bb4c", "id": 9}, {"samples": [{"hash": "kE0B3kMsI3a", "uri": "/contracts/kE0B3kMsI3a#terminated-program", "label": "Co Development and Option Agreement (Alector, Inc.)", "score": 30.0157432556, "published": true}, {"hash": "1WnmvkCFaL9", "uri": "/contracts/1WnmvkCFaL9#terminated-program", "label": "Co Development and Option Agreement (Alector, Inc.)", "score": 29.7775497437, "published": true}], "snippet": "means (a) with respect to the termination of this Agreement for a Collaboration Program pursuant to Sections 12.2 or 12.5, the Collaboration Program subject to such termination, (b) upon expiration of the Option Period for a Collaboration Program for which AbbVie has not previously delivered an Exercise Notice, such Collaboration Program, (c) with respect to the termination of this Agreement pursuant to Sections 12.2 or 12.5 for any AbbVie Opt In Product, the AbbVie Opt In Product subject to such termination and (d) with respect to termination of this Agreement in its entirety, all Collaboration Programs and all AbbVie Opt In Products.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [10, 25]}, {"key": "termination-of-this-agreement-for", "type": "clause", "offset": [30, 63]}, {"key": "pursuant-to-sections", "type": "clause", "offset": [88, 108]}, {"key": "the-collaboration", "type": "clause", "offset": [123, 140]}, {"key": "subject-to", "type": "clause", "offset": [149, 159]}, {"key": "the-option-period", "type": "clause", "offset": [201, 218]}, {"key": "exercise-notice", "type": "definition", "offset": [296, 311]}, {"key": "termination-and", "type": "clause", "offset": [502, 517]}, {"key": "termination-of-this-agreement-in-its-entirety", "type": "clause", "offset": [538, 583]}, {"key": "collaboration-programs", "type": "definition", "offset": [589, 611]}], "size": 2, "hash": "3288f5f12e317b1d611fbcb132f550f7", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbdGVybWluYXRlZC1wcm9ncmFtIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means (a) with respect to the termination of this Agreement with respect to a Program pursuant to Sections 9.2(a), 9.2(b) or 9.2(d), the Program subject to such termination; and (b) with respect to termination of this Agreement in its entirety, both Programs.", "size": 50, "title": "Terminated Program", "id": "terminated-program", "examples": ["Except as expressly stated to survive under Section 10.3.1(h), neither Party will have any further obligations with respect to the <strong>Terminated Program</strong> under the Collaboration Plan(s)."], "related": [["terminated-product", "Terminated Product", "Terminated Product"], ["licensed-program", "Licensed Program", "Licensed Program"], ["approved-program", "Approved program", "Approved program"], ["development-program", "Development Program", "Development Program"], ["development-activity", "Development Activity", "Development Activity"]], "related_snippets": [], "updated": "2025-08-01T04:31:04+00:00"}, "json": true, "cursor": ""}}